FDA rejection
FDA rejection
Merck’s $10B Deal and Breakthroughs in Hearing Restoration!
🌟 Merck acquires Verona for $10B! 🧬 Virtual Cell Challenge launched! 👂 Gene therapy shows promise for restoring hearing! 🔍 Fujifilm rebrands! 📅 BIO 2025 highlights!
FDA Releases Game-Changing CAR-T Guidelines: Everything You Need to Know!
📢 The FDA published new guidance for CAR-T cell products, covering change management, risk assessment, flow cytometry, and more. 👩🔬🔬🧪🗂 CAR-T FDA
SynaptixBio Receives FDA ODD for Leukodystrophy Treatment
📰 Rare disease specialist SynaptixBio Ltd receives FDA ODD for TUBB4A leukodystrophy, allowing research on therapy for isolated hypomyelination. 💊💡✨
Patient Advocate Slams FDA’s CAR-T Warning Labels: Is Patient Safety at Risk?
🔺 Patient advocate slams FDA decision on CAR-T warning labels, arguing it undermines patient knowledge and autonomy. 🔺 Warning labels may deter patients from seeking life-saving CAR-T therapies. 🔺 Advocates prioritize informed consent and patient education over warnings. 🔺 Critics fear labels could cause unnecessary fear and anxiety. 🔺 FDA decision raises concerns on patient safety vs. access to innovative therapies.
Alvotech’s Biosimilar Plant Receives Second FDA Violation
🔬🚨 Alvotech, a biopharmaceutical company, receives another FDA observation at its biosimilar plant, potentially delaying product approval.
Cell and Gene Therapy: $82B Market by 2032 – Trends Challenges and Innovations
📰 The global cell and gene therapy market is expected to reach $82.24 billion by 2032, with a current size of $15.54 billion in 2022. - Precedence Research 🧫 🔬 Gene therapy is seeing a rise in gene editing therapeutics, but cost and access remain challenges. 💉 📈 Autologous CAR-T cell therapies are moving to earlier treatment stages, while allogeneic cell therapies and solid tumor therapies are being developed. 🤖 💼 Collaboration and flexible regulatory pathways are key to advancing the industry and delivering therapies to patients. 💪
Astellas’ Gastric Cancer Treatment Rejected by FDA Blames CDMO
📢 Astellas' gastric cancer antibody rejected by FDA due to CDMO issues. Setback for treatment, importance of reliable CDMO highlighted. 😞🔍🏭📉💡
